Table Graph
      published meta-analysis   sensitivity analysis   studies

antiviral and associated therapy in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.86[0.59; 1.27]CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 202120%450moderatenot evaluable deaths (time to event analysis only)detailed resultsHYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24] 0.80[0.52; 1.24]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] 0.95[0.55; 1.64]CAP-China (Wang et al.), 202010%237NAnot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] 1.23[0.87; 1.74]CAP-China (Wang et al.), 202010%237NAnot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] 1.21[0.64; 2.28]CAP-China (Wang et al.), 202010%236NAnot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] 1.37[0.79; 2.39]CAP-China (Wang et al.), 202010%236NAnot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] 0.99[0.18; 5.51]CAP-China (Wang et al.), 202010%236NAnot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48] 1.13[0.89; 1.45]CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 202120%451moderatenot evaluable hospital dischargedetailed resultsHYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42] 1.01[0.72; 1.42]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable off oxygenationdetailed resultsHYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51] 0.98[0.64; 1.51]HYDRA (Hernandez-Cardenas), 202110%214NAnot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] 0.64[0.33; 1.23]CAP-China (Wang et al.), 202010%233NAnot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] 0.36[0.13; 1.01]CAP-China (Wang et al.), 202010%233NAnot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] 1.09[0.42; 2.79]CAP-China (Wang et al.), 202010%233NAnot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233NAnot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] 1.01[0.03; 30.33]CAP-China (Wang et al.), 202010%233NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-05-06 03:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons